3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Neoplasms
2
Hemorrhage
2
Thrombocytopenia
1
Recurrence
1
Postoperative Hemorrhage
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Blood Loss, Surgical
1
Interventions
venetoclax
27
fludarabine
26
Cyclophosphamide
25
Specimen Handling
21
Azacitidine
20
Biopsy
15
Whole-Body Irradiation
14
Stem Cell Transplantation
13
Decitabine
13
Cytarabine
13
Tacrolimus
12
Melphalan
12
fludarabine phosphate
11
Mycophenolic Acid
11
Busulfan
11
Injections
8
X-Rays
7
Thiotepa
7
Hematopoietic Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
decitabine and cedazuridine drug combination
6
Cyclosporine
6
ruxolitinib
5
Magnetic Resonance Spectroscopy
5
Idarubicin
5
Filgrastim
5
gilteritinib
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myelodysplastic Syndromes
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled